PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET
نویسندگان
چکیده
منابع مشابه
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
Checkpoint-blocking antibodies like those targeting the PD-1/PD-L1 pathway have revolutionized oncology. We developed radiotracers based on therapeutic checkpoint-blocking antibodies permitting sensitive and high-resolution PET imaging of both PD-1 and PD-L1 in immunocompetent mice. ImmunoPET of naive mice revealed similar overall expression patterns for PD-1 and PD-L1 in secondary lymphoid org...
متن کاملDiffuse high intensity PD-L1 staining in thymic epithelial tumors.
INTRODUCTION Blockade of the immune checkpoint programmed death receptor ligand-1 (PD-L1)/PD-1 pathway has well-established clinical activity across many tumor types. PD-L1 protein expression by immunohistochemistry is emerging as a predictive biomarker of response to these therapies. Here, we examine PD-L1 expression in a thymic epithelial tumor (TET) tissue microarray (TMA). METHODS The TMA...
متن کاملImmunohistochemical Expression of Pd-l1 in Solid Tumors
Recent clinical trials have demonstrated that it is possible to induce durable remission in several tumors (non-small cell lung cancer (NSCLC), melanoma, squamous cancer of head and neck, renal cell carcinoma, Hodgkin lymphoma, colorectal cancer) by blocking the PD-1/PD-L1 (programmed death-1/programmed death-ligand 1) axis with anti-PD-1 or antiPD-L1 antibodies and that an objective clinical r...
متن کاملPD-L1 and Survival in Solid Tumors: A Meta-Analysis
BACKGROUND Numerous agents targeting PD-L1/PD-1 check-point are in clinical development. However, the correlation between PD-L1 expression and prognosis of solid tumor is still in controversial. Here, we elicit a systematic review and meta-analysis to investigate the potential value of PD-L1 in the prognostic prediction in human solid tumors. METHODS Electronic databases were searched for stu...
متن کاملPD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
The therapy of different advanced-stage malignancies with monoclonal antibodies blocking programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling has had an impressive long-lasting effect in a portion of patients, but in most cases, this therapy was not successful, or a secondary resistance developed. To enhance its efficacy in treated patients, predictive biomarkers are searched ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bioconjugate Chemistry
سال: 2016
ISSN: 1043-1802,1520-4812
DOI: 10.1021/acs.bioconjchem.6b00348